Last Updated : June 26, 2024
Details
Generic Name:
fidaxomicin
Project Status:
Active
Therapeutic Area:
Clostridium difficile infection
Manufacturer:
Merck Canada Inc.
Call for patient/clinician input open:
Brand Name:
Dificid
Project Line:
Reimbursement Review
Project Number:
SF0847-000
Call for patient/clinician input closed:
NOC Status at Filing:
N/A
Biosimilar:
No
Manufacturer Requested Reimbursement Criteria1:
N/A
Submission Type:
Request for Advice
Fee Schedule:
N/A
Indications:
Clostridium difficile infection.
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.
| Call for patient/clinician input open | 05-Feb-24 |
|---|---|
| Request for Advice received | 29-Jan-24 |
| Manufacturer informed of request for advice | 31-Jan-24 |
| Manufacturer information or comments due | 14-Feb-24 |
| Request for Advice initiated | 15-Feb-24 |
| Call for patient/clinician input closed | 02-Apr-24 |
| Clarification: - Patient input submission received from the Gastrointestinal Society | |
| Draft CADTH review report(s) sent to sponsor | 16-Apr-24 |
| Deadline for sponsors comments | 25-Apr-24 |
| Expert committee meeting (initial) | 26-Jun-24 |
| Draft recommendation posted for stakeholder feedback | 18-Jul-24 |
| End of feedback period | 01-Aug-24 |
Last Updated : June 26, 2024